Thrombosis
News
FDA approves new treatment option for rare anemia
Pegcetacoplan (Empaveli) was approved as a treatment for paroxysmal nocturnal hemoglobinuria (PNH).
Conference Coverage
ADAPTABLE: Low-dose aspirin as good as high-dose in CHD?
A large randomized trial specifically designed to investigate the optimum dose of aspirin in patients with established coronary disease has found...
From the Journals
High teen BMI linked to stroke risk in young adulthood
Finding holds true for men and women, even for those individuals with BMIs in the high-normal range.
Conference Coverage
Cushing’s death rate ‘unacceptable,’ triple that of general population
Death rates among patients with endogenous Cushing’s syndrome have dropped since 2000 but are still threefold that of the general population.
News
FDA, CDC urge pause of J&J COVID vaccine
Treatment for traditional blood clots, such as the drug heparin, should not be used for these clots.
From the Journals
Novel antiplatelet drug: Hope for efficacy without bleeding?
A new antiplatelet drug with a completely novel mechanism of action could hold the promise of delivering the holy grail – reducing cardiac events...
From the Journals
Study suggests no added risk of blood clots in COVID-19 outpatients
From the Journals
AstraZeneca COVID vaccine: Clotting disorder mechanism revealed?
The vaccine may be linked to a condition that clinically resembles heparin-induced thrombocytopenia and seems to occur mainly in younger women.
From the Journals
New ASH guidelines: VTE prevention and treatment in cancer patients
From the Journals
Large study finds trans men on testosterone at risk for blood clots
Transgender men who take testosterone are at risk of developing erythrocytosis and future thrombotic events, especially if they smoke and are...
News from the FDA/CDC
FDA alert confirms heart and cancer risks with tofacitinib (Xeljanz)
Completed safety clinical trial shows occurrence of heart-related events and cancer in RA patients taking the Janus kinase inhibitor is higher...